• In July 2026, Surgery Partners, Inc. reaffirmed its 2026 earnings outlook, maintaining expected revenues in the range of US$3.35 billion to US$3.45 billion.
• This reaffirmed guidance underlines management’s confidence in operational execution and offers investors clearer visibility into the company’s near-term revenue expectations.
• Next, we’ll explore how reaffirming a US$3.35–US$3.45 billion revenue outlook may influence Surgery Partners’ investment narrative and risk profile.

Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Surgery Partners Investment Narrative Recap

To own Surgery Partners, you have to believe its outpatient surgery footprint can convert steady procedure demand into improving economics over time, despite current losses. The reaffirmed 2026 revenue outlook of US$3.35 billion to US$3.45 billion supports the near term growth story but does not remove key risks around leverage, rising interest costs, and the execution of acquisitions and facility optimization, so the core risk reward balance is largely unchanged by this update.

The most relevant recent announcement here is the Q1 2026 result, where revenue reached US$810.9 million while the company remained loss making. That print, followed by repeated guidance reaffirmations, ties the story together: Surgery Partners is signaling confidence that its existing facilities and pipeline can support the full year revenue range, while investors still need to watch whether those volumes translate into better margins and progress toward profitability.

Yet while guidance looks steady, investors should be aware that higher floating rate interest on US$2.2 billion of debt could still...

Surgery Partners' narrative projects $4.0 billion revenue and $72.9 million earnings by 2029.

Uncover how Surgery Partners' forecasts yield a $17.95 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts were already modeling only about 4.1 percent annual revenue growth and no profits by 2029, so even this reaffirmed US$3.35 billion to US$3.45 billion outlook may not change their more cautious focus on rising interest costs and leverage, and it is worth weighing that more pessimistic view alongside the consensus before deciding how you see the story playing out.

Explore 2 other fair value estimates on Surgery Partners - why the stock might be worth over 2x more than the current price!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Surgery Partners research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Surgery Partners research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Surgery Partners' overall financial health at a glance.

No Opportunity In Surgery Partners?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Find 51 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.